Skip to main content

Table 2 Comparison of baseline characteristics between groups 1 and 2

From: Volumetric magnetic resonance-guided high-intensity focused ultrasound ablation of uterine fibroids through abdominal scars: the impact of a scar patch on therapeutic efficacy and adverse effects

Characteristics All patients Group 1 Group 2 P value
Patients 76 21 55  
 Ages (years) 39.2 ± 5.8 (22.0–53.0) 40.3 ± 6.0 (29.0–53.0) 38.8 ± 5.9 (22.0–50.0) 0.331
 Body mass index (kg/m2) 19.8 ± 1.8 (17.2–25.4) 20.4 ± 2.1 (17.8–25.4) 19.6 ± 1.6 (17.2–24.2) 0.072
 Subcutaneous fat thickness (mm) 11.6 ± 4.8 (3.0–26.0) 14.3 ± 5.8 (3.0–26.0) 10.6 ± 3.9 (3.0–20.0) 0.002*
 Baseline symptom severity scorea 52.4 ± 16.1 (21.9–93.8) 51.9 ± 16.2 (21.9–87.5) 52.6 ± 16.3 (21.9–93.8) 0.871
 Main Symptoms
  Bulk effect 67 20 47 0.430
  AUB 39 10 29 0.799
 Uterus position 0.003*
  Anteverted 48 19 29  
  Retroverted 28 2 26  
Number of fibroid treated (total) 2.8 ± 3.1 (1–15) 2.6 ± 3.0 (1–12) 2.8 ± 3.1 (1–15) 0.805
  1fibroid 45 14 31  
  2–5 fibroids 18 4 14  
  6–9 fibroids 8 2 6  
  ≥ 10 fibroids 5 1 4  
 Diameter (cm)b 6.6 ± 2.6 (2.1–15.1) 6.2 ± 2.7 (2.6–15.0) 6.7 ± 2.6 (2.1–15.1) 0.494
 Volume (ml)b 157.3 ± 141.3 (6.0–794.0) 156.7 ± 164.7 (37.0–7.094) 157.5 ± 133.0 (6.0–637.0) 0.983
 Distance (mm)c 92.4 ± 17.0 (57.0–133.0) 90.7 ± 13.0 (57.0–117.0) 93.1 ± 18.3 (63.0–1.033) 0.581
 Bowel Displacement Techniqued     0.536
  Yes 58 15 43  
  No 18 6 12  
 Location     0.669
  Intramural 38 9 29  
  Subserosal 21 6 15  
  Submucosal 17 6 11  
  1. Values in parentheses represent ranges
  2. aTransformed symptom severity scores (SSS) can range from 0 to 100
  3. bLargest treated fibroids only
  4. cFrom Skin to the most posterior part of the largest fibroid
  5. dBowel displacement technique: sequential application of urinary bladder and rectal filling and urinary bladder emptying
  6. *Statistically significant